Published in N Engl J Med on July 19, 2001
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas | NCT01550523
British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax (2003) 5.83
Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ (2007) 3.26
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ (2011) 1.96
Epidemiology and risk factors for venous thrombosis. Semin Hematol (2007) 1.90
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med (2007) 1.54
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ (2007) 1.29
Epidemiology of venous thromboembolism. Nat Rev Cardiol (2015) 1.07
Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. Thromb J (2013) 1.05
Factors related to recurrence of paradoxical cerebral embolism due to patent foramen ovale. J Neurol (2011) 1.01
The epidemiology of venous thromboembolism. J Thromb Thrombolysis (2016) 1.00
Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One (2012) 0.96
Acute pulmonary embolism. Part 2: treatment. Nat Rev Cardiol (2010) 0.96
Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 0.96
Predicting the risk of venous thromboembolism recurrence. Am J Hematol (2012) 0.88
Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore) (2014) 0.86
Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med (2008) 0.86
Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol. BMC Pregnancy Childbirth (2012) 0.82
Oral heparin: status review. Thromb J (2006) 0.82
Recurrent venous thromboembolism: what is the risk and how to prevent it. Scientifica (Cairo) (2012) 0.82
The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wien Klin Wochenschr (2003) 0.81
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.79
Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. Curr Treat Options Cardiovasc Med (2013) 0.79
Improving anticoagulation therapy using point-of-care testing and a standardized protocol. Ann Fam Med (2008) 0.78
Systemic thrombolysis in the upper extremity deep vein thrombosis. ARYA Atheroscler (2011) 0.78
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open (2014) 0.76
Anticoagulation for venous thromboembolism. BMJ (2007) 0.76
Acute deep vein thrombosis cases in the real world. Semin Intervent Radiol (2012) 0.76
Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. Thrombosis (2010) 0.75
Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis. J Thromb Haemost (2014) 0.75
Update in general internal medicine. J Gen Intern Med (2009) 0.75
Optimal duration of anticoagulation in patients with venous thromboembolism. Indian J Med Res (2011) 0.75
Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. J Gen Intern Med (2003) 0.75
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res (2017) 0.75
Duration of anticoagulation for venous thromboembolic events. Circulation (2014) 0.75
3 months and 1 year of oral anticoagulant therapy were equivalent for idiopathic proximal deep venous thrombosis. ACP J Club (2002) 0.75
Anticoagulation for idiopathic deep-vein thrombosis. N Engl J Med (2001) 0.75
Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study). BMC Cardiovasc Disord (2013) 0.75
Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women. Haematologica (2010) 0.75
Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study. PLoS One (2016) 0.75
Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin. J Neurol (2007) 0.75
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Travel and risk of venous thrombosis. Lancet (2000) 5.23
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med (1989) 2.73
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med (1996) 2.51
Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med (2003) 2.28
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost (2015) 2.19
Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study. J Thromb Haemost (2005) 2.18
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost (2013) 2.15
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost (2010) 2.08
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost (2013) 2.05
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost (2012) 2.04
Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med (1998) 2.03
Deep-vein thrombosis. Lancet (1999) 1.98
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost (2003) 1.95
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost (2009) 1.95
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. J Thromb Haemost (2009) 1.68
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost (2004) 1.63
Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia (2010) 1.59
Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost (2001) 1.58
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost (2006) 1.55
Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up. J Thromb Haemost (2009) 1.55
Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost (2007) 1.54
Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost (2003) 1.54
Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism--an overview. Thromb Haemost (2000) 1.51
The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost (2008) 1.50
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal. J Thromb Haemost (2011) 1.45
A statistical 3-D pattern processing method for computer-aided detection of polyps in CT colonography. IEEE Trans Med Imaging (2001) 1.45
Can evidence harm? Certainly not hemophilia treatment and community. J Thromb Haemost (2006) 1.45
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev (2006) 1.44
Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost (1996) 1.42
Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Ann Intern Med (1998) 1.41
The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation. J Thromb Haemost (2012) 1.40
The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica (1997) 1.39
Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. J Thromb Haemost (2008) 1.39
Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost (2009) 1.35
Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost (1997) 1.27
Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med (1993) 1.26
The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia (2013) 1.24
Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost (1999) 1.23
Atrial fibrillation in elite athletes. J Cardiovasc Electrophysiol (1998) 1.23
Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost (2011) 1.22
Venous thrombosis from air travel: the LONFLIT3 study--prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial. Angiology (2002) 1.22
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost (2013) 1.21
Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res (2010) 1.18
Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med (1994) 1.17
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost (2013) 1.16
Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures. Leuk Lymphoma (2003) 1.15
A case report and literature review of portal vein thrombosis associated with cytomegalovirus infection in immunocompetent patients. Clin Infect Dis (2006) 1.14
An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. J Vasc Surg (1999) 1.13
Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost (2006) 1.11
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost (2012) 1.11
Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovasc Dis (2006) 1.08
Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation (2009) 1.07
Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost (2005) 1.07
Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer (1998) 1.07
Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol (2005) 1.06
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg (1997) 1.06
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost (2010) 1.06
Monilethrix treated with minoxidil. Int J Immunopathol Pharmacol (2011) 1.06
Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica (2001) 1.06
Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost (2011) 1.05
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: comment. J Thromb Haemost (2014) 1.05
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke (1995) 1.04
Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost (2010) 1.04
A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost (2000) 1.03
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood (2000) 1.02
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol (2013) 1.01
Cancer and venous thromboembolism. Am Heart J (1996) 1.01
Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost (1992) 1.00
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost (2008) 1.00
The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood (1999) 1.00
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost (2012) 0.99
Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol (2013) 0.99
Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol (1998) 0.98
The post-thrombotic syndrome. Curr Opin Pulm Med (2000) 0.98